FibroGen
Jack Li has extensive work experience in the field of biostatistics. Jack started their career as a Consultant Statistician at Lilly/Abbott/Pfizer in 1998 and then joined Novartis as a Sr. Statistician in 2003. Jack later became a Consultant Statistician at J&J/Novartis from 2006 to 2009. Jack then worked at Celgene as a Principal Statistician/Associate Director from 2009 to 2019. Following that, they held the role of Associate Director Biostatistics at Bristol Myers Squibb from 2019 to 2021. Currently, they are working as a Sr. Director Biostatistics at FibroGen, Inc.
Jack Li earned a PhD in Biostatistics from Rutgers University. The timeframe of their education is unknown.
This person is not in any teams
This person is not in any offices
FibroGen
FibroGen, Inc. is a science-based biopharmaceutical company discovering and developing a pipeline of first- in-class therapeutics. The Company is focused on fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer. Roxadustat, the Company's most advanced product candidate, is an oral small molecule inhibitor of HIF prolyl hydroxylase activity in Phase III clinical development for the treatment of anemia in chronic kidney disease (CKD), and is entering Phase III development for anemia in lower risk myelodysplastic syndromes (MDS). The Company has developed Pamrevlumab. Pamrevlumab is a proprietary therapeutic antibody to inhibit the activity of connective tissue growth factor (CTGF), a common factor in chronic fibrotic and proliferative disorders characterized by persistent and excessive scarring that can lead to organ dysfunction and failure.